See more : Madison Sports & Entertainment Inc. (MSET) Income Statement Analysis – Financial Results
Complete financial analysis of Amyris, Inc. (AMRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amyris, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- CMO Group PLC (CMO.L) Income Statement Analysis – Financial Results
- SungEel HiTech Co., Ltd. (365340.KQ) Income Statement Analysis – Financial Results
- AltaGas Ltd. (ALA.TO) Income Statement Analysis – Financial Results
- Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L) Income Statement Analysis – Financial Results
- SportsHero Limited (SHO.AX) Income Statement Analysis – Financial Results
Amyris, Inc. (AMRS)
About Amyris, Inc.
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 269.85M | 341.82M | 173.14M | 152.56M | 80.42M | 143.45M | 77.19M | 34.15M | 43.27M | 41.12M | 73.69M | 146.99M | 80.31M | 64.61M | 13.89M |
| Cost of Revenue | 258.67M | 155.14M | 87.81M | 76.19M | 38.91M | 63.83M | 56.68M | 37.37M | 33.20M | 38.25M | 77.31M | 155.62M | 70.52M | 60.43M | 10.36M |
| Gross Profit | 11.18M | 186.68M | 85.33M | 76.37M | 41.51M | 79.62M | 20.51M | -3.22M | 10.07M | 2.87M | -3.62M | -8.62M | 9.80M | 4.18M | 3.53M |
| Gross Profit Ratio | 4.14% | 54.61% | 49.28% | 50.06% | 51.62% | 55.50% | 26.58% | -9.43% | 23.27% | 6.97% | -4.91% | -5.87% | 12.20% | 6.47% | 25.40% |
| Research & Development | 110.22M | 94.29M | 71.68M | 71.46M | 68.69M | 56.84M | 51.41M | 44.64M | 49.66M | 56.07M | 73.63M | 87.32M | 55.25M | 38.26M | 30.31M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 493.63M | 257.81M | 137.07M | 126.59M | 86.92M | 63.03M | 47.72M | 56.26M | 55.44M | 57.05M | 78.72M | 83.23M | 40.39M | 23.56M | 16.62M |
| Other Expenses | 0.00 | -38.07M | -89.16M | -20.15M | 1.36M | -956.00K | -45.37M | -114.18M | -30.00M | -20.86M | -45.63M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 603.84M | 352.10M | 208.75M | 198.05M | 155.61M | 119.88M | 99.13M | 105.62M | 105.10M | 113.12M | 152.35M | 170.55M | 95.64M | 61.82M | 46.93M |
| Cost & Expenses | 862.51M | 507.24M | 296.56M | 274.23M | 194.52M | 183.71M | 155.81M | 143.00M | 138.30M | 151.37M | 229.66M | 326.16M | 166.16M | 122.25M | 57.29M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 258.00K | 264.00K | 387.00K | 162.00K | 1.47M | 1.54M | 1.54M | 448.00K | 1.38M |
| Interest Expense | 24.73M | 25.61M | 47.95M | 58.67M | 39.27M | 36.16M | 37.63M | 78.85M | 28.95M | 9.11M | 4.93M | 1.54M | 1.44M | 1.22M | 377.00K |
| Depreciation & Amortization | 27.27M | -25.38M | -77.04M | -20.15M | 4.92M | 11.36M | 11.37M | 12.92M | 14.97M | 16.64M | 14.57M | 11.08M | 7.28M | 5.78M | 2.63M |
| EBITDA | -514.21M | -190.80M | -200.46M | -141.83M | -112.74M | -41.22M | -115.83M | -118.46M | -225.62M | -5.61M | -200.13M | -166.55M | -81.53M | -51.42M | -39.40M |
| EBITDA Ratio | -190.55% | -55.82% | -115.78% | -92.97% | -140.19% | -28.73% | -150.05% | -346.86% | -521.36% | -13.64% | -271.56% | -113.31% | -101.51% | -79.58% | -283.58% |
| Operating Income | -592.67M | -165.42M | -123.42M | -121.67M | -120.95M | -40.26M | -85.92M | -148.53M | -99.83M | -119.62M | -201.82M | -179.17M | -83.79M | -63.41M | -43.40M |
| Operating Income Ratio | -219.63% | -48.39% | -71.29% | -79.76% | -150.40% | -28.07% | -111.31% | -434.90% | -230.69% | -290.90% | -273.86% | -121.89% | -104.33% | -98.14% | -312.41% |
| Total Other Income/Expenses | 54.04M | -106.89M | -200.43M | -120.46M | -28.16M | -36.84M | -10.86M | -69.05M | 102.49M | -116.14M | -3.23M | 213.00K | 2.96M | -1.39M | 857.00K |
| Income Before Tax | -538.63M | -272.31M | -323.85M | -242.14M | -211.35M | -77.10M | -86.78M | -217.58M | 2.66M | -235.75M | -205.05M | -178.96M | -80.83M | -64.80M | -42.54M |
| Income Before Tax Ratio | -199.60% | -79.67% | -187.05% | -158.72% | -262.81% | -53.75% | -112.42% | -637.09% | 6.15% | -573.35% | -278.25% | -121.75% | -100.64% | -100.30% | -306.24% |
| Income Tax Expense | -2.70M | -8.11M | 293.00K | 629.00K | -50.95M | 295.00K | 553.00K | 468.00K | 495.00K | -847.00K | 981.00K | 552.00K | -3.98M | 877.00K | -207.00K |
| Net Income | -535.93M | -264.20M | -324.14M | -242.77M | -211.35M | -77.39M | -87.33M | -217.95M | 2.29M | -235.11M | -205.14M | -178.87M | -81.87M | -64.46M | -41.86M |
| Net Income Ratio | -198.60% | -77.29% | -187.22% | -159.13% | -262.81% | -53.95% | -113.14% | -638.16% | 5.28% | -571.78% | -278.37% | -121.69% | -101.94% | -99.77% | -301.35% |
| EPS | -1.58 | -0.90 | -1.59 | -2.39 | -3.50 | -2.40 | -5.49 | -25.75 | 0.45 | -46.73 | -54.25 | -59.89 | -82.75 | -203.42 | -124.74 |
| EPS Diluted | -1.58 | -0.90 | -1.59 | -2.39 | -3.50 | -2.40 | -4.95 | -25.75 | 0.28 | -46.73 | -54.25 | -59.89 | -82.75 | -203.42 | -124.74 |
| Weighted Avg Shares Out | 339.33M | 292.34M | 203.60M | 101.37M | 60.36M | 32.25M | 15.90M | 8.46M | 5.23M | 5.03M | 3.78M | 2.99M | 989.36K | 316.87K | 335.61K |
| Weighted Avg Shares Out (Dil) | 339.33M | 292.67M | 203.60M | 101.37M | 60.36M | 32.25M | 17.64M | 8.46M | 8.12M | 5.03M | 3.78M | 2.99M | 989.36K | 316.87K | 335.61K |
From Spending Cash To Fermenting Money: Amyris Is Fit To Profit From High ROI Plants And Innovative Marketing
"Fit To Win," high ROI Capex and innovative marketing are reducing cash burn equaling 19% of H2 2022 and 26% of 2023 product sales, delivering positive cash flow in 2023. Barra Bonita changes everything. Mfg. efficiencies and 30-60% lower COGS...
7 Cheap Penny Stocks to Buy Before They Pop Off
It may seem a little crazy to talk about finding cheap penny stocks to buy at this time. The economy is cooling, and even blue-chip stocks are struggling to gain traction.
Amyris: Consumer Business Cost Breakdown
Supply chain problems appear to have caused elevated COGS and shipping and handling expenses, a problem faced by many beauty brands and DTC companies. Insourcing production and changing packaging will resolve some of these issues and help improve profitability.
Why Amyris Stock Tumbled This Week
A new loan facility caused some consternation.
Penny Stocks To Buy Now: 3 To Watch With Unusual Options Activity Today
Penny stocks with unusual options activity to watch today. The post Penny Stocks To Buy Now: 3 To Watch With Unusual Options Activity Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Recurring Marketing Exclusivity Deals Accelerate Amyris On Path To Profitability
Amyris' more frequent and larger "exclusivity" deals introduce a unique, recurring catalyst to its business model that enhances profitability and requires raising our earnings estimates. We're raising our EPS estimates from ($1.19) to ($0.22)/share for 2022, from ($0.36) to ($0.09)/share...
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Synthetic biology maker Amyris owns a 60% global market share for a product that's increasingly used in personal care products. Will it notch a profit in 2024?
Wall Street Stock Market Today: Penny Stocks To Watch Before Fed Meeting
What To Watch With 5 Hot Penny Stocks This Week The post Wall Street Stock Market Today: Penny Stocks To Watch Before Fed Meeting appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Stocks That Can Double Your Money According to Wall Street
The experts say these stocks aren't getting half the appreciation that they deserve.
Amyris, Inc. (AMRS) CEO John Melo on Q2 2022 Results - Earnings Call Transcript
Amyris, Inc. (NASDAQ:AMRS ) Q2 2022 Earnings Conference Call August 9, 2022 9:00 AM ET Company Participants Han Kieftenbeld - Chief Financial Officer John Melo - President & Chief Executive Officer Eduardo Alvarez - Chief Operating Officer Conference Call Participants...
Source: https://incomestatements.info
Category: Stock Reports